SCHEMBL30765909

SCHEMBL30765909

C[C@@H](N)c1nc(-c2ccccc2)co1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ENPP3 O14638 7/20 0.43
ENPP1 P22413 5/20 0.43
HSD11B1 P28845 2/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
RAB9A P51151 2/20 0.38
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
ASIC3 Q9UHC3 1/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
DAGLA Q9Y4D2 1/20 0.35
TP53 P04637 1/20 0.35
NR3C2 P08235 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10052155 0.85 ENPP3 (0.45) ENPP3ENPP1HSD11B1MEN1KMT2A
SCHEMBL21180807 0.82 ENPP3 (0.43) ENPP3ENPP1HSD11B1MEN1KMT2A
SCHEMBL6668389 0.82 ENPP3 (0.43) ENPP3ENPP1HSD11B1MEN1KMT2A
SCHEMBL13848629 0.79 ENPP3 (0.44) ENPP3ENPP1HSD11B1MEN1KMT2A
SCHEMBL13744630 0.77 ENPP3 (0.42) ENPP3ENPP1HSD11B1MEN1KMT2A
SCHEMBL30003076 0.74 PGR (0.40) ENPP3ENPP1HSD11B1ADORA2AADORA1
SCHEMBL31558543 0.74 HSD11B1 (0.35) ENPP3ENPP1HSD11B1MEN1KMT2A
Benzene SCHEMBL7220483 0.73
SCHEMBL2265105 0.71 ENPP3 (0.68) ENPP3ENPP1HSD11B1MEN1KMT2A
SCHEMBL8119166 0.71 LTA4H (0.54) ENPP3ENPP1HSD11B1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed